A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

This study is testing olutasidenib — a targeted oral drug — in patients with a specific gene mutation called IDH1 who have clonal cytopenia of undetermined significance (CCUS) or lower-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). These are conditions where bone marrow does not produce blood cells properly. **You may be eligible if...** - You are 18 or older with confirmed CCUS, lower-risk MDS, or lower-risk CMML - Your bone marrow or blood tests show a specific IDH1 mutation with a variant allele frequency of at least 2% - You have low blood counts (anemia, low neutrophils, or low platelets) that are unexplained - Your liver and kidney function are adequate - You are in reasonably good health (ECOG 0–2) **You may NOT be eligible if...** - Your IDH1 mutation has not been confirmed - You have high-risk MDS or AML (acute leukemia) - You have significant liver, kidney, or heart problems - You are pregnant or breastfeeding - You are on certain conflicting medications (such as strong CYP3A4 inducers) Talk to your doctor to see if this trial is right for you.